Study record
Senolytics in idiopathic pulmonary fibrosis: first-in-human, open-label pilot (Justice et al., 2019)
Human open-label pilot (feasibility / biomarker)
○ Evidence tier 3 — Human open-label pilot (feasibility / biomarker)
Record
| Design | First-in-human open-label pilot |
| N | 14 |
| Registry | NCT02874989 |
| PMID | 30616998 |
| DOI | 10.1016/j.ebiom.2018.12.052 |
| Citation status | pmid+doi verified via PubMed eutils (EBioMedicine 2019;40:554-563; PMC6412088); NCT02874989 from websearch |
Five-qualifier claim
| Species / population | Adults with idiopathic pulmonary fibrosis (n=14), two-centre open-label pilot. |
| Exposure, route, schedule | Oral dasatinib 100 mg/day + quercetin 1250 mg/day, 3 days/week over 3 weeks (intermittent). |
| Comparator / duration | Open-label / single-blind feasibility design; ~3-week intervention with short follow-up. |
| Endpoint / numeric result | Primary endpoints were feasibility (retention/completion); most consistent secondary improvement was in physical function/mobility measures (e.g. 6-minute walk, gait speed, chair-stands). |
| What it did NOT establish | Not powered for efficacy; no lung-function disease-modification claim; no lifespan outcome. |
Interventions
Primary reference
https://clinicaltrials.gov/study/NCT02874989
Exact identifier to be confirmed against the primary record before publication where flagged above.